European Myeloma Network B.v.

This study tests a drug called teclistamab in 30 people with AL amyloidosis, a rare disease where abnormal proteins damage organs. Participants have already had other treatments. The goal is to see if teclistamab can reduce or eliminate the harmful proteins in the blood. The stud…

This phase 2 trial tests whether adding the drug daratumumab to a standard chemotherapy combination (bortezomib, cyclophosphamide, and dexamethasone) works better than the current standard (bortezomib, thalidomide, and dexamethasone) for newly diagnosed multiple myeloma patients …

This phase 3 trial tests whether adding the targeted antibody isatuximab to a standard three-drug regimen (carfilzomib, lenalidomide, dexamethasone) can achieve deeper remissions in people newly diagnosed with multiple myeloma who are eligible for a stem cell transplant. Particip…

This phase 3 trial tests whether a combination of selinexor, pomalidomide, and dexamethasone works better than elotuzumab, pomalidomide, and dexamethasone for people with multiple myeloma that has come back or stopped responding to treatment. About 117 participants who have alrea…